CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas leaders position state to become next global hub for brain health

event recap

Brain Capital: The New Competitive Edge in a Shifting Economy, a two-day meeting held at the TMC3 Collaborative Building on May 21-22, brought together global business and policy leaders to advance brain health initiatives. The event concluded with the announcement of Texas-focused strategies that will be presented at the G7 Summit in Calgary this June, aiming to position the state as a leading hub for brain health research.

According to an analysis by the McKinsey Health Institute, investing in brain health interventions has the potential to generate a $260 billion boost to Texas’ GDP. Brain health conditions are responsible for more than $1 trillion in lost productivity globally, and the costs are expected to increase to nearly $16 trillion by 2030, according to organizers of the event.

The Texas Legislature recently passed legislation to establish the Dementia Prevention Research Institute of Texas (DPRIT), which includes a $3 billion investment over 10 years. Leaders at the Brain Capital event announced the launch of an advocacy campaign to foster support for DPRIT, which will appear as a November 2025 ballot measure.

“Our work to deliver better brain health to Texas and the world is only just beginning,” Dr. Jochen Reiser, president of The University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System, said in a news release. “Investing in brain capital means protecting our cognitive health, boosting economic growth and securing a future-ready workforce – goals that we believe Texans will rally behind.”

Additionally, the Center for Houston’s Future also announced its goal to make the brain economy a key part of its new plan for the Houston region, called Vision 2050. The Center for Houston’s Future’s goal is to position Houston to become the global leader in the brain economy space, which will serve as a blueprint for other cities

“Houston has a clear track record leading the transition of industry sectors,” David Gow, CEO of the Center for Houston’s Future, said in a news release. “By launching a focused Brain Economy transition plan, Houston can integrate neuroscience, prevention, workforce resilience and cognitive innovation across sectors – preparing businesses and communities for an AI-driven future. Houston has the talent, infrastructure and vision to lead the nation in the next great economic transformation.”

Gow is the founder and chairman of Gow Media, InnovationMap's parent company.

Speakers at the event included executives from Shell Oil Co., scientists from Johns Hopkins Bloomberg School of Public Health, professors from Rice University, representatives from D.C.-based UsAgainstAlzheimer’s, and others. Learn more here.

Houston boasts No. 2 biggest population gain in U.S., Census data shows

Boomtown

Houston saw the second-highest population increase in the United States in 2024, according to the U.S. Census Bureau.

The new population report revealed Houston gained 43,217 residents from July 2023 to July 2024, bringing the city's population to 2,390,125.

Houston hung on to its ranking as the fourth largest city in the country and joined 11 other Southern cities that saw the largest numeric population gains in 2024, the report added.

Elsewhere in Texas, Fort Worth is now home to more than 1 million residents, surpassing Austin as the 11th largest city in the U.S. Fort Worth had the fifth-highest numeric increase in population, adding 23,442 residents during that same time frame to bring the city's total population to 1,008,106 residents.

Dallas retained its No. 9 spot on the list of the 15 most populous cities in the U.S. The city gained more than 23,000 residents during the one-year period, bringing its population to 1,326,087 people in 2024.


Austin slipped two spots and now ranks as the 13th largest city after adding more than 13,000 residents to bring the Texas Capital's population to 993,588.

San Antonio gained 23,945 residents — the fourth-highest increase nationwide — and was the only other city besides Houston to have a higher numerical growth rate than Fort Worth during the one-year period.

Fastest-growing U.S. cities
Princeton, a North Texas suburb of Dallas, topped the charts as the No. 1 fastest-growing U.S. city in 2024. The Census Bureau says the city's population has more than doubled in the last five years to more than 37,000 residents.

Fulshear, 34 miles from downtown Houston, has continued its rapid expansion as the second-fastest growing city. The suburb grew nearly 27 percent since the previous year, and its population rose to 54,629 residents as of July 2024.

Five additional Texas cities made the list of fastest-growing U.S. cities:

  • Celina, near Dallas (No. 4) with 18.2 percent growth (51,661 total population)
  • Anna, near Dallas (No. 5) with 14.6 percent growth (31,986 total population)
  • Fate, near Dallas (No. 8) with 11.4 percent growth (27,467 total population)
  • Melissa, near Dallas (No. 11) with 10 percent growth (26,194 total population)
  • Hutto, near Austin (No. 13) with 9.4 percent growth (42,661 total population)

The Austin suburb of Georgetown's growth has continued to slow down since 2023, and it no longer appears in the list of fastest-growing cities. However, it did surpass 100,000 residents in 2024. San Angelo, a small city in West Texas, also surpassed the 100,000-population threshold.

Most populous U.S. cities in 2024
New York City maintained its stronghold as the biggest in America in 2024, boasting a population of nearly 8.5 million residents. Los Angeles and Chicago also retained second and third place, with respective populations of nearly 3.88 million and more than 2.7 million residents.

"Cities in the Northeast that had experienced population declines in 2023 are now experiencing significant population growth, on average," said Crystal Delbé, a statistician in the Census Bureau’s Population Division. "In fact, cities of all sizes, in all regions, showed faster growth and larger gains than in 2023, except for small cities in the South, whose average population growth rate remained the same."

The 15 populous U.S. cities as of July 1, 2024 were:

  • No. 1 – New York, New York (8.48 million)
  • No. 2 – Los Angeles, California (3.88 million)
  • No. 3 – Chicago, Illinois (2.72 million)
  • No. 4 – Houston, Texas (2.39 million)
  • No. 5 – Phoenix, Arizona (1.67 million)
  • No. 6 – Philadelphia, Pennsylvania (1.57 million)
  • No. 7 – San Antonio, Texas (1.53 million)
  • No. 8 – San Diego, California (1.4 million)
  • No. 9 – Dallas, Texas (1.33 million)
  • No. 10 – Jacksonville, Florida (1 million)
  • No. 11 – Fort Worth, Texas (1 million)
  • No. 12 – San Jose, California (997,368)
  • No. 13 – Austin, Texas (993,588)
  • No. 14 – Charlotte, North Carolina (943,476)
  • No. 15 – Columbus, Ohio (933,263)
---

A version of this article originally appeared on CultureMap.com.

Houston VC firm closes $21M fund for underrepresented founders

fresh funding

Houston-based South Loop Ventures recently closed its debut fund for more than $21 million, led by investments from Rice Management Company and Chevron Technology Ventures.

The funds will go toward teams with at least one underrepresented founder of color working in the energy, health, space, sports and fintech sectors. Additional investments came from The Great Commission Foundation of the Episcopal Diocese of Texas, Texas CapitalBank and others organizations.

According to South Loop Ventures, less than 3 percent of venture capital reaches underrepresented founders of color. Zach Ellis Jr., founder and general partner of South Loop, says the firm wants to address this "billion-dollar blind spot."

"Inequitable distribution of venture capital represents a clear market inefficiency—and market inefficiencies translate into exceptional opportunities," Ellis said in a release.

He added that the firm's location in Houston will help it make an impact.

"Being anchored here gives us front-row access to world-class corporations eager to engage and support innovation from founders with underrepresented voices and perspectives," he added in the release.

Ellis founded South Loop Ventures in 2022. It has funded 13 companies since August 2023 and plans to fund several more this year. Its portfolio includes Houston-based Milkify, a breast milk freeze-drying service; Lokum App, a Houston-founded platform for recruiting certified registered nurse anesthetists; and others.

Ellis' background spans the United States Military, academia, and roles at Rev1 Ventures and PepsiCo’s corporate venture team. He previously told InnovationMap that he was called to invest in founders of color after George Floyd's murder. He says he also realized how much money was being left on the table by overlooking these innovators.

"The mission of South Loop is to become the preeminent source of venture capital dollars for underrepresented, diverse teams nationally to serve as a beacon for the best underrepresented talent and to enable them to be successful through leveraging the unique resources and talent of Houston," he said on the Houston Innovators Podcast in 2024. "A big part of our mission is also to help catalyze Houston as an ecosystem for tech entrepreneurship."

Listen to the full interview with Ellis here. The recent funding news and Ellis were also featured in a profile by TechCrunch earlier this week. Click here to read more.